Argenica Therapeutics Ltd
Argenica Therapeutics Establishes Expert Committee to Advance Phase 2b Stroke Trial
Argenica Therapeutics forms Clinical Advisory Committee to accelerate ARG-007 Phase 2b stroke trial.
Argenica Study Confirms Compatibility of ARG-007 Candidate with Stroke Treatment Standard-of-Care Therapies
Argenica Therapeutics (ASX: AGN) has reported positive results from a drug-to-drug interaction assessment showing its lead candidate ARG-007 does not interfere with clot-dissolving agent tenecteplase in the treatment of acute ischemic stroke.
Argenica Therapeutics Validates Efficacious ARG-007 Dose in New Pre-Clinical Stroke Study
Argenica Therapeutics (ASX: AGN) has released new data from an independent pre-clinical study validating the efficacy and dosing of lead neuroprotective peptide candidate ARG-007 for ischaemic stroke.
Argenica Therapeutics Releases Positive Safety Data from Phase 2 ARG-007 Stroke Trial
Perth-based biotech Argenica Therapeutics (ASX: AGN) has released top-line safety results from its Phase 2 trial evaluating lead candidate ARG-007 on patients with acute ischaemic stroke (AIS) who are undergoing mechanical removal of a blood clot in the brain. The multi-centre, double-blind, randomised, placebo-controlled, single-dose clinical study conducted by the company’s clinical research organisation ProPharma […]